Tissue Factor Pathway Inhibitors As Potential Targets for Understanding the Pathophysiology of Preeclampsia

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 May 27

PMID 37238908

Authors

Hiroshi Kobayashi

Sho Matsubara

Chiharu Yoshimoto

Hiroshi Shigetomi

Shogo Imanaka

Affiliations

Soon will be listed here.

Abstract

Background: Preeclampsia is a hypertensive disorder of pregnancy that causes maternal and perinatal morbidity and mortality worldwide. Preeclampsia is associated with complex abnormalities of the coagulation and fibrinolytic system. Tissue factor (TF) is involved in the hemostatic system during pregnancy, while the Tissue Factor Pathway Inhibitor (TFPI) is a major physiological inhibitor of the TF-initiated coagulation cascade. The imbalance in hemostatic mechanisms may lead to a hypercoagulable state, but prior research has not comprehensively investigated the roles of TFPI1 and TFPI2 in preeclamptic patients. In this review, we summarize our current understanding of the biological functions of TFPI1 and TFPI2 and discuss future directions in preeclampsia research.

Methods: A literature search was performed from inception to 30 June 2022 in the PubMed and Google Scholar databases.

Results: TFPI1 and TFPI2 are homologues with different protease inhibitory activities in the coagulation and fibrinolysis system. TFPI1 is an essential physiological inhibitor of the TF-initiated extrinsic pathway of coagulation. On the other hand, TFPI2 inhibits plasmin-mediated fibrinolysis and exerts antifibrinolytic activity. It also inhibits plasmin-mediated inactivation of clotting factors and maintains a hypercoagulable state. Furthermore, in contrast to TFPI1, TFPI2 suppresses trophoblast cell proliferation and invasion and promotes cell apoptosis. TFPI1 and TFPI2 may play important roles in regulating the coagulation and fibrinolytic system and trophoblast invasion to establish and maintain successful pregnancies. Concentrations of TF, TFPI1, and TFPI2 in maternal blood and placental tissue are significantly altered in preeclamptic women compared to normal pregnancies.

Conclusions: TFPI protein family may affect both the anticoagulant (i.e., TFPI1) and antifibrinolytic/procoagulant (i.e., TFPI2) systems. TFPI1 and TFPI2 may function as new predictive biomarkers for preeclampsia and navigate precision therapy.

Citing Articles

Investigating tissue factor pathway inhibitor and other protease and protease inhibitors and their association with major adverse aortic events in patients with abdominal aortic aneurysm.

Khan H, Zamzam A, Shaikh F, Saposnik G, Mamdani M, Qadura M Res Pract Thromb Haemost. 2025; 9(1):102645.

PMID: 39816169 PMC: 11732669. DOI: 10.1016/j.rpth.2024.102645.

Effect of tissue factor pathway inhibitor on the pyroptosis of vascular smooth muscle cells induced by angiotensin II.

Dai Y, Xu R, Yang K, Jiang T, Wei Y, Liu Y Cardiovasc Diagn Ther. 2024; 14(1):72-83.

PMID: 38434568 PMC: 10904294. DOI: 10.21037/cdt-23-355.

Whole transcriptome profiling of placental pathobiology in SARS-CoV-2 pregnancies identifies placental dysfunction signatures.

Stylianou N, Sebina I, Matigian N, Monkman J, Doehler H, Rohl J Clin Transl Immunology. 2024; 13(2):e1488.

PMID: 38322491 PMC: 10846628. DOI: 10.1002/cti2.1488.

Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?.

Marques I, Tavares V, Neto B, Mota I, Pereira D, Medeiros R Int J Mol Sci. 2023; 24(15).

PMID: 37569483 PMC: 10418965. DOI: 10.3390/ijms241512103.

References

Zhang Q, Zhang Y, Wang S, Wang N, Jiang W, Ji Y . Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. J Exp Clin Cancer Res. 2012; 31:1. PMC: 3314549. DOI: 10.1186/1756-9966-31-1. View

Wojtukiewicz M, Sierko E, Zimnoch L, Kozlowski L, Kisiel W . Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost. 2003; 90(1):140-6. View

Rao C, Lakka S, Kin Y, Konduri S, Fuller G, Mohanam S . Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res. 2001; 7(3):570-6. View

Greer I, Aharon A, Brenner B, Gris J . Coagulation and placenta-mediated complications. Rambam Maimonides Med J. 2014; 5(4):e0034. PMC: 4222423. DOI: 10.5041/RMMJ.10168. View

Wang G, Xie B, Su Y, Gu Q, Hao D, Liu H . Expression analysis of tissue factor pathway inhibitors TFPI-1 and TFPI-2 in Paralichthys olivaceus and antibacterial and anticancer activity of derived peptides. Vet Res. 2021; 52(1):32. PMC: 7905887. DOI: 10.1186/s13567-021-00908-y. View

MacDonald T, Tong S, Myers J, Cannon P, Nguyen T, Keenan E . Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. Placenta. 2021; 105:32-40. DOI: 10.1016/j.placenta.2021.01.018. View

Teng Y, Lin Q, Lin J, Ding C, Zuo Y . Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J Perinat Med. 2009; 37(4):343-8. DOI: 10.1515/JPM.2009.060. View

Sprecher C, Kisiel W, Mathewes S, Foster D . Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A. 1994; 91(8):3353-7. PMC: 43575. DOI: 10.1073/pnas.91.8.3353. View

Boer K, den Hollander I, Meijers J, Levi M . Tissue factor-dependent blood coagulation is enhanced following delivery irrespective of the mode of delivery. J Thromb Haemost. 2007; 5(12):2415-20. DOI: 10.1111/j.1538-7836.2007.02767.x. View

10.

Zelaya H, Rothmeier A, Ruf W . Tissue factor at the crossroad of coagulation and cell signaling. J Thromb Haemost. 2018; 16(10):1941-1952. DOI: 10.1111/jth.14246. View

11.

Lockwood C, Krikun G, Schatz F . The decidua regulates hemostasis in human endometrium. Semin Reprod Endocrinol. 1999; 17(1):45-51. DOI: 10.1055/s-2007-1016211. View

12.

Xiong Y, Zhou Q, Jiang F, Zhou S, Lou Y, Guo Q . Changes of plasma and placental tissue factor pathway inhibitor-2 in women with preeclampsia and normal pregnancy. Thromb Res. 2010; 125(6):e317-22. DOI: 10.1016/j.thromres.2010.02.017. View

13.

Ota Y, Koizume S, Nakamura Y, Yoshihara M, Takahashi T, Sato S . Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix. Oncol Rep. 2021; 45(3):1023-1032. PMC: 7859994. DOI: 10.3892/or.2021.7944. View

14.

Maroney S, Ferrel J, Pan S, White T, Simari R, Mcvey J . Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost. 2009; 7(7):1106-13. PMC: 2776060. DOI: 10.1111/j.1538-7836.2009.03454.x. View

15.

Maroney S, Mast A . New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost. 2015; 13 Suppl 1:S200-7. PMC: 4604745. DOI: 10.1111/jth.12897. View

16.

Izumi H, Takahashi C, Oh J, Noda M . Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett. 2000; 481(1):31-6. DOI: 10.1016/s0014-5793(00)01902-5. View

17.

Mastrolia S, Mazor M, Loverro G, Klaitman V, Erez O . Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes. PeerJ. 2014; 2:e653. PMC: 4243334. DOI: 10.7717/peerj.653. View

18.

Butzow R, Alfthan H, Stenman U, Suikkari A, Bohn H, Seppala M . Immunofluorometric demonstration and quantification of placental protein 5 in the absence of pregnancy. Clin Chem. 1988; 34(8):1591-3. View

19.

Sierko E, Wojtukiewicz M, Kisiel W . The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost. 2007; 33(7):653-9. DOI: 10.1055/s-2007-991532. View

20.

Fei X, Wang H, Yuan W, Wo M, Jiang L . Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. Biomed Res Int. 2017; 2017:8983763. PMC: 5299162. DOI: 10.1155/2017/8983763. View